KR20230015946A - 예를 들어 우울증의 치료 방법에 사용하기 위한 gpr139 길항제로서의 3-((1h-피라졸-4-일)메틸)-6'-(페닐)-2h-(1,2'-비피리딘)-2-온 유도체 및 관련 화합물 - Google Patents
예를 들어 우울증의 치료 방법에 사용하기 위한 gpr139 길항제로서의 3-((1h-피라졸-4-일)메틸)-6'-(페닐)-2h-(1,2'-비피리딘)-2-온 유도체 및 관련 화합물 Download PDFInfo
- Publication number
- KR20230015946A KR20230015946A KR1020227044430A KR20227044430A KR20230015946A KR 20230015946 A KR20230015946 A KR 20230015946A KR 1020227044430 A KR1020227044430 A KR 1020227044430A KR 20227044430 A KR20227044430 A KR 20227044430A KR 20230015946 A KR20230015946 A KR 20230015946A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- compound
- ethyl
- group
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2020-090111 | 2020-05-22 | ||
| JP2020090111A JP2021183587A (ja) | 2020-05-22 | 2020-05-22 | 複素環化合物 |
| PCT/IB2021/000337 WO2021234451A1 (en) | 2020-05-22 | 2021-05-20 | 3-((1h-pyrazol-4-yl)methyl)-6'-(phenyl)-2h-(1,2'-bipyridin)-2-one derivatives and related compounds as gpr139 antagonists for use in a method of treatment of e.g. depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230015946A true KR20230015946A (ko) | 2023-01-31 |
Family
ID=76797026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227044430A Pending KR20230015946A (ko) | 2020-05-22 | 2021-05-20 | 예를 들어 우울증의 치료 방법에 사용하기 위한 gpr139 길항제로서의 3-((1h-피라졸-4-일)메틸)-6'-(페닐)-2h-(1,2'-비피리딘)-2-온 유도체 및 관련 화합물 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12590086B2 (https=) |
| EP (1) | EP4153581A1 (https=) |
| JP (3) | JP2021183587A (https=) |
| KR (1) | KR20230015946A (https=) |
| CN (1) | CN116171276A (https=) |
| AR (1) | AR122143A1 (https=) |
| AU (1) | AU2021276623A1 (https=) |
| BR (1) | BR112022023503A2 (https=) |
| CA (1) | CA3178798A1 (https=) |
| IL (1) | IL298275A (https=) |
| MX (1) | MX2022014576A (https=) |
| TW (1) | TW202208346A (https=) |
| WO (1) | WO2021234451A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021183587A (ja) * | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| GB202206054D0 (en) * | 2022-04-26 | 2022-06-08 | Cerevance Ltd | Novel Compounds |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001500852A (ja) | 1996-08-27 | 2001-01-23 | プレーシス ファーマスーティカルズ インコーポレイテッド | Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター |
| DE19736352C1 (de) | 1997-08-21 | 1998-12-10 | Atotech Deutschland Gmbh | Vorrichtung zur Kontaktierung von flachem Behandlungsgut in Durchlaufgalvanisieranlagen |
| CA2374610A1 (en) | 1999-06-28 | 2001-01-04 | Jordan J. N. Tang | Catalytically active recombinant memapsin and methods of use thereof |
| ATE448784T1 (de) | 2002-02-14 | 2009-12-15 | Pharmacia Corp | Substituierte pyridinone als modulatoren für p38 map kinase |
| US8148367B2 (en) | 2007-01-12 | 2012-04-03 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
| WO2008094556A2 (en) | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists |
| WO2011145735A1 (ja) | 2010-05-21 | 2011-11-24 | 武田薬品工業株式会社 | チアゾール誘導体 |
| WO2017222952A1 (en) | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| PL3829581T3 (pl) | 2018-07-27 | 2024-07-01 | Arcus Biosciences, Inc. | Antagoniści pirydonu a2r |
| WO2020097609A1 (en) * | 2018-11-09 | 2020-05-14 | Blackthorn Therapeutics, Inc. | Gpr139 receptor modulators |
| JP2020090111A (ja) | 2018-12-03 | 2020-06-11 | パイオニア株式会社 | 発光システム |
| JP2021183586A (ja) | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2021183587A (ja) | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
-
2020
- 2020-05-22 JP JP2020090111A patent/JP2021183587A/ja active Pending
-
2021
- 2021-05-20 JP JP2022570532A patent/JP7734153B2/ja active Active
- 2021-05-20 US US17/999,514 patent/US12590086B2/en active Active
- 2021-05-20 TW TW110118337A patent/TW202208346A/zh unknown
- 2021-05-20 CA CA3178798A patent/CA3178798A1/en active Pending
- 2021-05-20 BR BR112022023503A patent/BR112022023503A2/pt unknown
- 2021-05-20 CN CN202180059093.3A patent/CN116171276A/zh active Pending
- 2021-05-20 AR ARP210101387A patent/AR122143A1/es unknown
- 2021-05-20 IL IL298275A patent/IL298275A/en unknown
- 2021-05-20 WO PCT/IB2021/000337 patent/WO2021234451A1/en not_active Ceased
- 2021-05-20 AU AU2021276623A patent/AU2021276623A1/en active Pending
- 2021-05-20 EP EP21737769.6A patent/EP4153581A1/en active Pending
- 2021-05-20 MX MX2022014576A patent/MX2022014576A/es unknown
- 2021-05-20 KR KR1020227044430A patent/KR20230015946A/ko active Pending
-
2025
- 2025-08-25 JP JP2025139595A patent/JP2025170366A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12590086B2 (en) | 2026-03-31 |
| US20230357220A1 (en) | 2023-11-09 |
| TW202208346A (zh) | 2022-03-01 |
| AU2021276623A1 (en) | 2022-12-22 |
| AR122143A1 (es) | 2022-08-17 |
| CN116171276A (zh) | 2023-05-26 |
| WO2021234451A1 (en) | 2021-11-25 |
| JP7734153B2 (ja) | 2025-09-04 |
| IL298275A (en) | 2023-01-01 |
| MX2022014576A (es) | 2023-02-14 |
| EP4153581A1 (en) | 2023-03-29 |
| JP2023528281A (ja) | 2023-07-04 |
| CA3178798A1 (en) | 2021-11-25 |
| BR112022023503A2 (pt) | 2023-01-17 |
| JP2025170366A (ja) | 2025-11-18 |
| JP2021183587A (ja) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7379374B2 (ja) | 複素環化合物 | |
| CA3019298A1 (en) | Heterocyclic compound | |
| CA3163200A1 (en) | Heterocyclic compound | |
| US11827601B2 (en) | Heterocyclic NMDA antagonists | |
| JP2025168429A (ja) | 例えば、うつ病を治療するための、ｇｐｒ１３９拮抗薬としての１－（（１ｈ－ピラゾール－４－イル）メチル）－３－（フェニル）－１，３－ジヒドロ－２ｈ－イミダゾール－２－オン誘導体および関連化合物 | |
| EP3239150B1 (en) | Heterocyclic compound | |
| JP2025170366A (ja) | 例えばうつ病の治療方法において使用するためのｇｐｒ１３９拮抗薬としての３－（（１ｈ－ピラゾール－４－イル）メチル）－６’－（フェニル）－２ｈ－（１，２’－ビピリジン）－２－オン誘導体および関連化合物 | |
| JP7541487B2 (ja) | 複素環化合物及びその用途 | |
| WO2019022179A1 (ja) | 複素環化合物 | |
| JP2025539434A (ja) | 複素環化合物及びその用途 | |
| BR112020018238A2 (pt) | Compostos heterocíclicos e uso dos mesmos | |
| EA051899B1 (ru) | Производные 3-((1н-пиразол-4-ил)метил)-6'-(фенил)-2н-(1,2'-бипиридин)-2-она и связанные с ними соединения как антагонисты рецептора gpr139 для применения в способе лечения, например, депрессии | |
| KR20250155550A (ko) | 매크로시클릭 헤테로시클 화합물 및 이의 용도 | |
| HK40059391A (en) | Heterocyclic compound and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |